Uveal Melanoma Drivers Identified as Potential Drug Targets
Researchers have found that two proteins sustain tumor growth, opening new avenues for treatment in adults.
Updated on Oct. 2, 2026 in Cancer
Scientists have identified the proteins p300 and CBP as critical vulnerabilities in uveal melanoma, the most common eye cancer in adults. This finding highlights a new pathway for therapeutic intervention by targeting how these cancers maintain their growth.
Why it matters
Uveal melanoma often relies on mutated GNAQ genes to drive tumor survival through complex signaling. By pinpointing p300 and CBP as key components of this process, researchers have revealed a potential way to disrupt the mechanisms that allow these tumors to grow and spread.
Using an isogenic CRISPR screening approach in laboratory models, researchers demonstrated that p300 and CBP interact with YAP at chromatin to fuel gene transcription. Pharmacological inhibition of these proteins successfully impaired tumor growth and metastasis in vivo during this preclinical study.
The players
YAP
A protein signaling molecule that functions as a transcriptional co-activator to drive uncontrolled cellular growth in many cancer types.
p300
A lysine acetyltransferase protein that, along with its paralogue CBP, regulates gene expression by modifying chromatin structure.
The details
The cancer cells in uveal melanoma utilize mutated GNAQ genes to initiate a signaling cascade that relies on the protein YAP. The proteins p300 and CBP function by binding to YAP at DNA sites, increasing H3K27 acetylation to turn on growth-promoting genes. This complex recruits RNA polymerase II and CDK9, effectively locking the tumor into a state of constant, unrestrained growth.
Timeline
October 2, 2026: Findings were formally published.
Health Landscape
This research expands the understanding of YAP-dependent transcriptional signaling, which is a major focus for cancer therapy development. It provides a more precise target for disrupting the growth mechanisms of uveal melanoma that standard treatments currently struggle to contain.
While this is a preclinical finding, it clarifies the specific biological drivers of uveal melanoma that may inform future clinical trials. Patients managing this condition should discuss emerging targeted therapy developments and their potential relevance to personalized care plans with an oncologist.
The takeaway
Targeting the interaction between p300, CBP, and YAP appears to be a promising strategy for limiting the progression of uveal melanoma. Patients and caregivers should continue to monitor updates on targeted therapy research for updates that could eventually influence standard care protocols.
Further reading
For a deeper look at the evolution of new oncology interventions, explore our coverage in Cancer.
More information
Review the technical findings regarding these protein pathways in the peer-reviewed research article.
Source note: This article includes information reported by Nature.
